Targeting lentiviruses to infect chosen cells
靶向慢病毒感染选定的细胞
基本信息
- 批准号:7762182
- 负责人:
- 金额:$ 60.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-02-01 至 2012-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAlphavirusAnimal ModelAntibodiesAntibody RepertoireAntigensAura virusBaltimoreBindingBiomedical EngineeringCD20 AntigensCD34 geneCellsChemokine (C-C Motif) Receptor 5Chimeric ProteinsCollaborationsCytoplasmic TailCytosolDNADataDendritic CellsDengue VirusDiseaseEndocytosisEndosomesEngineeringEnvironmentEpitopesFlavivirusGene DeliveryGenerationsGlycoproteinsGoalsHIVHematopoietic stem cellsHumanImmunologyIn SituIn VitroInborn Errors of MetabolismIndividualInfectionIntentionIntravenousLaboratoriesLeadLentivirus VectorLightMS4A1 geneMalignant NeoplasmsMammalian CellMediatingMembraneMembrane FusionMethodsMolecularMolecular ModelsMonitorMusOrganPreparationProcessProductionProteinsProto-Oncogene Protein c-kitRecombinantsResearch PersonnelRoss river virusSemliki forest virusSmall Interfering RNAStem Cell FactorStructureStudy SectionSubfamily lentivirinaeSurfaceSystemTherapeuticTick-Borne Encephalitis VirusTick-Borne Encephalitis VirusesTissuesVaccinationViralVirionVirusVirus DiseasesWorkcancer therapycell typedesigngene delivery systemgene therapyimprovedin vivomelanomamolecular modelingneoplastic cellnovelnovel strategiesprogramsreceptorreceptor bindingrecombinant virusresearch studytooltositumomabvectorvirologyvpr Gene Products
项目摘要
Gene therapy is amenable for correcting inborn errors of metabolism, as well as for the treatment of cancer
and HIV.Lentiviral vectors are among the most efficient tools for gene delivery into mammalian cells. Our
long-term goal is to develop a targetable gene delivery system that can transduce a specific cell type, a
specific tissue or a specific organ after intravenous adminstration. Our preliminary studies have uncovered a
truly targetable lentiviral vector system for gene delivery. The experimental focus of this proposal is to
evaluate the therapeutic potential of this method for in vivo targeting. The first specific aim is to study the
molecular mechanism of targeted infection by engineered recombinant viruses. Understanding this process
should lead to identification and design of new molecules for targeting. The second specific aim is to perfect
the strategy to prepare lentiviruses, which will greatly enhance the efficacy of virus preparation. The third
specific aim is to explore novel molecules for targeting lentiviral vectors, which will expand our ability to
manipulate lentiviruses for targeting. The fourth specific aim is to explore the utility of targeted gene delivery
using antibody- and SCF-bearing lentiviruses. These studies build upon our novel finding that viruses
displaying membrane-bound antibodies or stem cell factor (SCF) can specifically infect cells expressing
cognate antigens or SCF receptors. Various experiments are proposed to assess the therapeutic
implications of this novel targeting strategy to treat HIV and cancer in animal models. Taken together, these
novel studies will enlarge the therapeutic potential of targeted gene delivery to treat a diverse range of
diseases, as well as advance our undstanding of viral infection.
基因疗法适用于纠正先天性代谢错误以及癌症的治疗
慢病毒载体是将基因传递到哺乳动物细胞的最有效工具之一。我们的
长期目标是开发一种可转导特定细胞类型的靶向基因传递系统,
静脉给药后作用于特定组织或特定器官。我们的初步研究发现
用于基因传递的真正靶向慢病毒载体系统。本提案的实验重点是
评估该方法体内靶向的治疗潜力。第一个具体目标是研究
工程重组病毒靶向感染的分子机制。了解这个过程
应该导致识别和设计新的靶向分子。第二个具体目标是完善
慢病毒的制备策略,将大大提高病毒制备的效率。第三个
具体目标是探索针对慢病毒载体的新分子,这将扩展我们的能力
操纵慢病毒进行靶向。第四个具体目标是探索靶向基因递送的效用
使用携带抗体和 SCF 的慢病毒。这些研究建立在我们的新发现之上,即病毒
展示膜结合抗体或干细胞因子(SCF)可以特异性感染表达的细胞
同源抗原或 SCF 受体。提出了各种实验来评估治疗效果
这种新颖的靶向策略在动物模型中治疗艾滋病毒和癌症的意义。综合起来,这些
新颖的研究将扩大靶向基因递送的治疗潜力,以治疗多种疾病
疾病,并增进我们对病毒感染的了解。
项目成果
期刊论文数量(19)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment.
通过交联多层脂质体共同递送卡铂和紫杉醇用于卵巢癌治疗。
- DOI:10.1039/c7ra01100h
- 发表时间:2017
- 期刊:
- 影响因子:3.9
- 作者:Zhang,Xiaoyang;Liu,Yarong;Kim,YuJeong;Mac,John;Zhuang,Rachel;Wang,Pin
- 通讯作者:Wang,Pin
Gamma-retroviral vectors enveloped with an antibody and an engineered fusogenic protein achieved antigen-specific targeting.
- DOI:10.1002/bit.21903
- 发表时间:2008-10-01
- 期刊:
- 影响因子:3.8
- 作者:Yang, Haiguang;Ziegler, Leslie;Joo, Kye-Il;Cho, Taehoon;Lei, Yuning;Wang, Pin
- 通讯作者:Wang, Pin
Lentiviral vectors for immune cells targeting.
- DOI:10.3109/08923970903420582
- 发表时间:2010-06
- 期刊:
- 影响因子:3.3
- 作者:Froelich S;Tai A;Wang P
- 通讯作者:Wang P
In Vitro Differentiation of Adult Bone Marrow Progenitors into Antigen-Specific CD4 Helper T Cells Using Engineered Stromal Cells Expressing a Notch Ligand and a MHC Class II protein.
使用表达 Notch 配体和 MHC II 类蛋白的工程基质细胞将成体骨髓祖细胞体外分化为抗原特异性 CD4 辅助 T 细胞。
- DOI:10.1089/scd.2008.0021
- 发表时间:2008
- 期刊:
- 影响因子:4
- 作者:Wang,Pin;Dai,Bingbing
- 通讯作者:Dai,Bingbing
Immunization delivered by lentiviral vectors for cancer and infectious diseases.
- DOI:10.1111/j.1600-065x.2010.00967.x
- 发表时间:2011-01
- 期刊:
- 影响因子:8.7
- 作者:Hu B;Tai A;Wang P
- 通讯作者:Wang P
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pin Wang其他文献
Pin Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pin Wang', 18)}}的其他基金
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity
MART-1 TCR 基因转移抗黑色素瘤免疫的优化
- 批准号:
7782236 - 财政年份:2009
- 资助金额:
$ 60.37万 - 项目类别:
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity
MART-1 TCR 基因转移抗黑色素瘤免疫的优化
- 批准号:
8627567 - 财政年份:
- 资助金额:
$ 60.37万 - 项目类别:
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity
MART-1 TCR 基因转移抗黑色素瘤免疫的优化
- 批准号:
8375422 - 财政年份:
- 资助金额:
$ 60.37万 - 项目类别:
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity
MART-1 TCR 基因转移抗黑色素瘤免疫的优化
- 批准号:
8239560 - 财政年份:
- 资助金额:
$ 60.37万 - 项目类别:
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity
MART-1 TCR 基因转移抗黑色素瘤免疫的优化
- 批准号:
8448003 - 财政年份:
- 资助金额:
$ 60.37万 - 项目类别:
相似国自然基金
新发猪肠道甲型冠状病毒的细胞入侵及跨种传播的分子机制研究
- 批准号:31872488
- 批准年份:2018
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Employing viruses to unravel the functional significance of the m5C epitranscriptome
利用病毒揭示 m5C 表观转录组的功能意义
- 批准号:
10638533 - 财政年份:2023
- 资助金额:
$ 60.37万 - 项目类别:
Pandemic preparedness research and biocontainment infrastructure at The Rockefeller University
洛克菲勒大学的流行病防范研究和生物防护基础设施
- 批准号:
10611639 - 财政年份:2022
- 资助金额:
$ 60.37万 - 项目类别:
Development of Broad Spectrum Direct Acting Antivirals Against Emerging Alphaviruses
针对新兴甲病毒的广谱直接作用抗病毒药物的开发
- 批准号:
10513688 - 财政年份:2022
- 资助金额:
$ 60.37万 - 项目类别:
Project 5: Pandemic Virus Helicase Inhibitors
项目5:大流行病毒解旋酶抑制剂
- 批准号:
10522814 - 财政年份:2022
- 资助金额:
$ 60.37万 - 项目类别: